Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surabgene Lomparvovec (ABBV-RGX-314) in Neovascular Age-Related Macular Degeneration (nAMD)
NCT07007065Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2025
- Primary completion
- Mar 2033
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 17
01
Overview
A Phase 3 trial of surabgene lomparvovec in neovascular age-related macular degeneration (NVAMD), sponsored by AbbVie Inc.. Started Nov 2025; status: recruiting.
02
Drugs
surabgene lomparvovec
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT07007065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07007065.